Harrow (NASDAQ:HROW - Get Free Report) is anticipated to release its earnings data after the market closes on Monday, March 17th. Analysts expect Harrow to post earnings of ($0.01) per share and revenue of $58.41 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Harrow Trading Down 1.8 %
Harrow stock traded down $0.41 during mid-day trading on Thursday, hitting $22.15. The company's stock had a trading volume of 191,965 shares, compared to its average volume of 350,347. Harrow has a 12 month low of $9.30 and a 12 month high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The business has a 50 day moving average price of $31.00 and a 200-day moving average price of $39.14. The stock has a market cap of $788.77 million, a price-to-earnings ratio of -23.60 and a beta of 0.69.
Analysts Set New Price Targets
A number of research firms have recently weighed in on HROW. B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th. HC Wainwright began coverage on shares of Harrow in a report on Thursday, February 6th. They set a "buy" rating and a $57.00 target price for the company.
Check Out Our Latest Report on Harrow
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
